BIA
BBIO icon

Bell Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Bell Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Hold
223
– – ﹤0.01% 533
2026
Q1 		$16.6K Sell
223
-7
-3% -$507 ﹤0.01% 505
2025
Q4 		$17.6K Buy
230
+7
+3% +$459 ﹤0.01% 489
2025
Q3 		$11.6K Hold
223
– – ﹤0.01% 584
2025
Q2 		$9.63K Hold
223
– – ﹤0.01% 687
2025
Q1 		$7.71K Hold
223
– – ﹤0.01% 711
2024
Q4 		$6.12K Buy
223
+49
+28% +$1.27K ﹤0.01% 829
2024
Q3 		$4.43K Sell
174
-19
-10% -$499 ﹤0.01% 1000
2024
Q2 		$4.89K Hold
193
– – ﹤0.01% 929
2024
Q1 		$5.97K Hold
193
– – ﹤0.01% 831
2023
Q4 		$7.79K Buy
+193
New +$5.8K ﹤0.01% 654
2021
Q4 		$0 Sell
13
-115
-90% -$4.87K ﹤0.01% 1776
2021
Q3 		$6K Buy
+128
New +$6.86K ﹤0.01% 610

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bell Investment Advisors's BBIO Position: Q2 2026 in Review

Bell Investment Advisors held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 223 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

Bell Investment Advisors first reported a position in BBIO in Q3 2021 and has held it in 13 quarters since. The position peaked at $17.6K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bell Investment Advisors held 223 shares of BridgeBio Pharma worth $16.6K as of Q2 2026.
  • Bell Investment Advisors left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #533 holding.
  • Bell Investment Advisors first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 13 quarters since.
  • Bell Investment Advisors's BridgeBio Pharma position peaked at $17.6K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.